REPORT ID 4552

EMEA (Europe, Middle East and Africa) Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017

Publish Date
18-Dec-17
Pages
101
Format
Electronic (PDF)

In this report, the EMEA Resistant Pseudomonas Aeruginosa Infections Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Resistant Pseudomonas Aeruginosa Infections Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Resistant Pseudomonas Aeruginosa Infections Drugs market competition by top manufacturers/players, with Resistant Pseudomonas Aeruginosa Infections Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    ContraFect Corp
    Inhibrx LP
    Achaogen Inc
    LegoChem Biosciences Inc
    Melinta Therapeutics Inc
    Novartis AG
    AmpliPhi Biosciences Corp
    Biolytics Pharma
    Shionogi & Co Ltd

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Semi-Synthetic Penicillin
    Cephalosporin
    Lactam Drugs
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Home Care

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Resistant Pseudomonas Aeruginosa Infections Drugs Market Report 2017
1 Resistant Pseudomonas Aeruginosa Infections Drugs Overview
    1.1 Product Overview and Scope of Resistant Pseudomonas Aeruginosa Infections Drugs
    1.2 Classification of Resistant Pseudomonas Aeruginosa Infections Drugs
        1.2.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Semi-Synthetic Penicillin
        1.2.4 Cephalosporin
        1.2.5 Lactam Drugs
        1.2.6 Others
    1.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application/End Users
        1.3.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Home Care
    1.4 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market by Region
        1.4.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Resistant Pseudomonas Aeruginosa Infections Drugs (2012-2022)
        1.5.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs (Volume) by Application
    2.4 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs (Volume and Value) by Region
        2.4.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Price by Region (2012-2017)

3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        3.1.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type
    3.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Application
    3.4 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)

4 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type
    4.3 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Application
    4.4 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)

5 Africa Resistant Pseudomonas Aeruginosa Infections Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Value (2012-2017)
        5.1.1 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Type
    5.3 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Market Share by Application
    5.4 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate (2012-2017)

6 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers/Players Profiles and Sales Data
    6.1 ContraFect Corp
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Inhibrx LP
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Achaogen Inc
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 LegoChem Biosciences Inc
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Melinta Therapeutics Inc
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Novartis AG
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 AmpliPhi Biosciences Corp
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Biolytics Pharma
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Shionogi & Co Ltd
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Resistant Pseudomonas Aeruginosa Infections Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview

7 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Cost Analysis
    7.1 Resistant Pseudomonas Aeruginosa Infections Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Resistant Pseudomonas Aeruginosa Infections Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast (2017-2022)
    11.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Dat